Vaccine Packaging Companies Strategic Expansion Initiatives, Revenue Diversification, Strategic Joint Ventures

Vaccine Packaging Manufacturers and Market Growth

The global vaccine packaging market size is expected to attain USD 3.52 billion by 2034, rising from USD 1.94 billion in 2024, at a compound annual growth rate (CAGR) of 6.14% from 2024 to 2034.

Recent Developments by Market Companies

• In July 2024, a new initiative was launched with the goal of accelerating research and development and making human avian influenza (H5N1) messenger RNA (mRNA) vaccine candidates more accessible to manufacturers in low- and middle-income nations. This initiative will be led by the Argentine producer Sinergium Biotech, which will make use of the Medicines Patent Pool (MPP) mRNA Technology Transfer Programme and the World Health Organization (WHO).
• In June 2024, The U.S. Food and Drug Administration (FDA) received an amended Emergency Use Authorization for Novavax, Inc.'s revised JN.1 COVID-19 vaccine (NVX-CoV2705) for use in people 12 years of age and older. The proposal complies with the World Health Organization's (WHO), European Medicines Agency's (EMA), and U.S. FDA's guidelines to focus on the JN.1 lineage. The JN.1 vaccine from Novavax has shown broad cross-neutralizing antibodies against a variety of variant strains, such as KP.2 and KP.3, suggesting that it may be able to defend against forward drift variations.
• In May 2024, Moderna, Inc. declared that mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine was authorized by the U.S. Food and Drug Administration (FDA) to defend against lower respiratory tract sickness in the adults sixty years of age and above that is brought on by RSV infection. The approval, which becomes Moderna's second approved mRNA product, was given under the category of breakthrough therapy. The RSV vaccine that comes in a pre-filled syringe which is intended to be as simple to use as possible, saving vaccinators time and lowering the possibility of administrative errors is mRESVIA.
• January, 2024: SCHOTT Pharma announced the launch of new glass vials intended for deep-cold medicine storage. EVERIC® freeze vials can tolerate the -80°C storage temperatures required for vaccinations, gene therapy, and mRNA medications. New vials with strength-optimized design lowers breaking risk avoid losing life-saving drugs and expensive downtime.
• February, 2023: West Pharmaceutical Services, Inc. expanded its partnership with Corning Incorporated to include exclusive distribution rights for Corning Valor® Glass vials. The company additionally unveiled its initial offering, West Ready Pack™ with Corning Valor® RTU Vials making use of SG EZ-fill® technology.

Vaccine Packaging Market Companies

• Schott AG
• Gerresheimer AG
• Stevanato GroupSGD Pharma
• Nipro Corporation
• Corning Incorporated
• West Pharmaceutical Services, Inc.
• AptarGroup, Inc.
• Becton, Dickinson and Company (BD)
• Catalent, Inc.

US Import Data for Vaccine Packaging Market: Insights on Vials, Ampoules, Pre-filled Syringes, and Insulated Packaging